Savara Inc. (NASDAQ:SVRA) Receives Consensus Rating of “Moderate Buy” from Brokerages

Savara Inc. (NASDAQ:SVRA) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $9.00.

SVRA has been the topic of a number of research reports. Oppenheimer set a $10.00 target price on shares of Savara in a report on Tuesday, December 23rd. Guggenheim reiterated a “buy” rating on shares of Savara in a research report on Tuesday, December 23rd. Wells Fargo & Company boosted their price objective on Savara from $7.00 to $9.00 and gave the stock an “overweight” rating in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Thursday, January 22nd. Finally, Wall Street Zen lowered Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of SVRA. Polar Capital Holdings Plc bought a new position in Savara during the fourth quarter valued at $50,086,000. RTW Investments LP purchased a new position in shares of Savara during the 4th quarter worth about $35,893,000. VR Adviser LLC boosted its stake in shares of Savara by 172.7% during the 2nd quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock worth $20,256,000 after purchasing an additional 5,626,624 shares during the period. Marshall Wace LLP bought a new position in Savara during the 4th quarter valued at about $27,496,000. Finally, Spruce Street Capital LP bought a new position in Savara during the 4th quarter valued at about $14,539,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Savara Stock Down 0.6%

NASDAQ SVRA opened at $5.25 on Friday. The stock has a 50 day moving average price of $5.55 and a 200-day moving average price of $5.05. Savara has a one year low of $1.89 and a one year high of $7.01. The company has a debt-to-equity ratio of 0.15, a quick ratio of 11.85 and a current ratio of 11.85. The company has a market capitalization of $1.07 billion, a P/E ratio of -9.91 and a beta of 0.31.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Friday, March 13th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.01). As a group, equities analysts predict that Savara will post -0.45 EPS for the current fiscal year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.